AffyXell Therapeutics Co., Ltd. presented the results of the Efficacy PoC evaluation of AFX001, a genetically engineered MSC under development for acute graft-versus-host disease (aGVHD), at the International Society for Cell Therapy (ISCT 2023) held in Paris, France.

AFX001 is an MSC therapeutic designed to secreted Affimer^® molecules targeting CD40L based on AffyXell’s platform technology.

AffyXell confirmed the clinical score improvement through the xenograft GVHD model, and explained that the treatment effect of GVHD can be expected by suppressing the activity of T cells and B cells.

Currently, AffyXell Therapeutics Co., Ltd. is conducting non-clinical trials for IND submission of AFX001 for aGVHD.